Trial · NCT00240331
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Randomised Participants With a Major Cardiovascular Event (Non-fatal Stroke, Non-fatal Myocardial Infarction or Cardiovascular Death) | Rosuvastatin 10mg | 396 | Participants | ||
| Number of Randomised Participants With a Major Cardiovascular Event (Non-fatal Stroke, Non-fatal Myocardial Infarction or Cardiovascular Death) | Placebo | 408 | Participants | ||
| Number of Randomised Participants That Died From Any Cause. | Rosuvastatin 10mg | 636 | Participants | ||
| Number of Randomised Participants That Died From Any Cause. | Placebo | 660 | Participants | ||
| Number of Randomised Participants With a Major Cardiovascular Event or That Died From Any Known Cause | Rosuvastatin 10mg | 614 | Participants | ||
| Number of Randomised Participants With a Major Cardiovascular Event or That Died From Any Known Cause | Placebo | 645 | Participants | ||
| Number of Randomised Participants That Died From Cardiovascular Cause | Rosuvastatin 10mg | 324 | Participants | ||
| Number of Randomised Participants That Died From Cardiovascular Cause | Placebo | 324 | Participants | ||
| Number of Randomised Participants With an Atherosclerotic Cardiac Event (Non-fatal Myocardial Infarction or Coronary Heart Disease (CHD) Death) | Rosuvastatin 10mg | 258 | Participants | ||
| Number of Randomised Participants With an Atherosclerotic Cardiac Event (Non-fatal Myocardial Infarction or Coronary Heart Disease (CHD) Death) | Placebo | 256 | Participants | ||
| Number of Randomised Participants That Experienced a Procedure as a Result of Stenosis or Thrombosis of the Vascular Access (Arteriovenous (AV) Fistulas and Grafts Only) for Haemodialysis. | Rosuvastatin 10mg | 390 | Participants | ||
| Number of Randomised Participants That Experienced a Procedure as a Result of Stenosis or Thrombosis of the Vascular Access (Arteriovenous (AV) Fistulas and Grafts Only) for Haemodialysis. | Placebo | 360 | Participants | ||
| Number of Randomised Participants That Experienced a Coronary or Peripheral Revascularisation (Including Above Ankle Limb Amputations). | Rosuvastatin 10mg | 148 | Participants | ||
| Number of Randomised Participants That Experienced a Coronary or Peripheral Revascularisation (Including Above Ankle Limb Amputations). | Placebo | 152 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00240331/results